ORAPRED Drug Patent Profile
✉ Email this page to a colleague
When do Orapred patents expire, and when can generic versions of Orapred launch?
Orapred is a drug marketed by Concordia Pharms Inc and is included in two NDAs.
The generic ingredient in ORAPRED is prednisolone sodium phosphate. There are eighty-eight drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the prednisolone sodium phosphate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Orapred
A generic version of ORAPRED was approved as prednisolone sodium phosphate by BAUSCH AND LOMB on July 29th, 1994.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ORAPRED?
- What are the global sales for ORAPRED?
- What is Average Wholesale Price for ORAPRED?
Summary for ORAPRED
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 5 |
| Clinical Trials: | 8 |
| Drug Prices: | Drug price information for ORAPRED |
| What excipients (inactive ingredients) are in ORAPRED? | ORAPRED excipients list |
| DailyMed Link: | ORAPRED at DailyMed |
Recent Clinical Trials for ORAPRED
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Chulalongkorn University | N/A |
| University of Florida | Phase 4 |
| University of California, San Francisco | Phase 4 |
US Patents and Regulatory Information for ORAPRED
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Concordia Pharms Inc | ORAPRED | prednisolone sodium phosphate | SOLUTION;ORAL | 075117-001 | Dec 14, 2000 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Concordia Pharms Inc | ORAPRED ODT | prednisolone sodium phosphate | TABLET, ORALLY DISINTEGRATING;ORAL | 021959-003 | Jun 1, 2006 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Concordia Pharms Inc | ORAPRED ODT | prednisolone sodium phosphate | TABLET, ORALLY DISINTEGRATING;ORAL | 021959-001 | Jun 1, 2006 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
